본문으로 건너뛰기
← 뒤로

Combination of hsa-miR-21-3p/ sTNF-RI/ IL12-p40 /CCL25 serves as a promising panel of diagnostic biomarkers for distinguishing malignant from benign nodules in papillary thyroid cancer.

1/5 보강
Endocrine 📖 저널 OA 26.4% 2022: 9/35 OA 2023: 14/49 OA 2024: 14/69 OA 2025: 18/63 OA 2026: 8/22 OA 2022~2026 2026 Vol.91(1) OA Thyroid Cancer Diagnosis and Treatme
Retraction 확인
출처
PubMed DOI OpenAlex 마지막 보강 2026-04-29
OpenAlex 토픽 · Thyroid Cancer Diagnosis and Treatment MicroRNA in disease regulation Thyroid Disorders and Treatments

Aytatli A, Sahin A, Barlak N, Caglar HO, Gundogdu B, Tatar A

이 논문을 인용하기

↓ .bib ↓ .ris
APA Abdulmelik Aytatlı, Abdulkadir Şahin, et al. (2026). Combination of hsa-miR-21-3p/ sTNF-RI/ IL12-p40 /CCL25 serves as a promising panel of diagnostic biomarkers for distinguishing malignant from benign nodules in papillary thyroid cancer.. Endocrine, 91(1). https://doi.org/10.1007/s12020-026-04612-9
MLA Abdulmelik Aytatlı, et al.. "Combination of hsa-miR-21-3p/ sTNF-RI/ IL12-p40 /CCL25 serves as a promising panel of diagnostic biomarkers for distinguishing malignant from benign nodules in papillary thyroid cancer.." Endocrine, vol. 91, no. 1, 2026.
PMID 42043718 ↗

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🔓 OA PDF 열기